UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 6, 2006
Lifeline Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Colorado
|
|
000-30489
|
|
90-0224471 |
|
|
|
|
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.) |
of incorporation) |
|
|
|
|
6400 South Fiddlers Green Circle, Suite 1970, Greenwood Village, CO 80111
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code: (720) 488-1711
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM 7.01 Regulation FD Disclosure
Beginning December 6, 2006 and thereafter, management of the company intends to hold
discussions and/or meetings with investors. The attached presentation, dated December 2006,
includes the information to be discussed. The presentation is attached as Exhibit 99.1 hereto.
ITEM 9.01. Exhibits
99.1 Presentation entitled IR Presentation.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: December 6, 2006
|
|
|
|
|
|
LIFELINE THERAPEUTICS, INC.
|
|
|
By: |
/s/ Stephen K. Onody
|
|
|
|
Stephen K. Onody |
|
|
|
Chief Executive Officer |
|
2